Zhongshan Hospital Xiamen University
🇨🇳China
Clinical Trials
18
Active:2
Completed:2
Trial Phases
4 Phases
Phase 1:3
Phase 2:3
Phase 4:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Not Applicable
6 (40.0%)Phase 1
3 (20.0%)Phase 2
3 (20.0%)Phase 4
3 (20.0%)Mechanism and Application of Vitamin D in Idiopathic Sudden Sensorineural Hearing Loss
Not Applicable
Active, not recruiting
- Conditions
- Idiopathic Sudden Sensorineural Hearing Loss
- Interventions
- Drug: Vitamin D Supplementation+ standard treatmentOther: standard treatment
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 197
- Registration Number
- NCT07045883
- Locations
- 🇨🇳
Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China
Exploring the Risk Factors of Otomycosis: A Case-Control Study
Recruiting
- Conditions
- Otomycosis
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 200
- Registration Number
- NCT06530069
- Locations
- 🇨🇳
Zhongshan Hospital of Xiamen university, Xiamen, Fujian, China
Efficacy of Self vs. Physician Application of Triamcinolone-Econazole in Otomycosis
Phase 4
Completed
- Conditions
- Otomycosis
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 200
- Registration Number
- NCT06431542
- Locations
- 🇨🇳
Xiamen University Zhongshan Hospital, Xiamen, Fujian, China
Effect of Carbon Dioxide Insufflation and Appendix on the Restoration of Intestinal Microecology After Colonoscopy.
Active, not recruiting
- Conditions
- ColonoscopyGastrointestinal MicrobiomeCarbon Dioxide InsufflationAppendix
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 38
- Registration Number
- NCT05637021
- Locations
- 🇨🇳
Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study
Phase 2
- Conditions
- Stage IV Gastric Cancer With Metastasis
- Interventions
- Drug: Camrelizumab; Nab-paclitaxel; S-1
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 33
- Registration Number
- NCT05441254
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found